Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma | MicrobiomeTrials← Back to trialsNCT06517017
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-10-09Est. Completion: 2026-11
Enrollment target: 40 participants Locations- Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States
Other microbiome trials you might be interested in
Multiple Myeloma
The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexame…
Duarte, United StatesEst. completion Oct 31, 2028
Relapsed/Refractory Multiple Myeloma
This trial is a single-arm, open-label, multicenter phase I/II clinical study of LBL-034 in patients with RRMM to evalua…
Wuhu, ChinaEst. completion Oct 20, 2026